Dr Reddy's Laboratories rose 0.84% to Rs 2311.70 at 10:08 IST on BSE after the company said it has received an Establishment Inspection Report from the US drug regulator for units located in Medak district, Telangana.
The announcement was made during trading hours today, 28 June 2018.Meanwhile, the S&P BSE Sensex was up 50.96 points, or 0.14% to 35,268.07.
On the BSE, 24,000 shares were traded in the counter so far compared with average daily volumes of 1.51 lakh shares in the past two weeks. The stock had hit a high of Rs 2324.40 and a low of Rs 2284.30 so far during the day. The stock hit a 52-week high of Rs 2,788 on 24 July 2017. The stock hit a 52-week low of Rs 1,888 on 21 May 2018.
Further to intimation dated 9 March 2018 and 16 March 2018 with regard to the audit of API Hyderabad Plant 3 at Bollaram, Medak District, Telangana and API Hyderabad Plant 1 at Jinnaram Mandal, Medak District, Telangana, respectively, Dr Reddy's Laboratories informed that it has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA), for both of the above-referred facilities.
Dr Reddy's Laboratories' consolidated net profit fell 19.4% to Rs 272.10 crore on 0.54% fall in net sales to Rs 3534.90 crore in Q4 March 2018 over Q4 March 2017.
Dr Reddy's Laboratories is an integrated pharmaceutical company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
